A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse.

Trial Profile

A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2015

At a glance

  • Drugs Farletuzumab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Morphotek
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov record (NCT00318370).
    • 09 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record (NCT00318370).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top